Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDYIN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THETRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE
Autore:
BIRKETT DJ; MCMANUS P;
Indirizzi:
FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT CLIN PHARMACOL BEDFORD PK SA 5042 AUSTRALIA FLINDERS UNIV S AUSTRALIA,DEPT CLIN PHARMACOL ADELAIDE SA 5001 AUSTRALIA AUSTRALIAN DEPT HUMAN SERV & HLTH,PHARMACEUT BENEFITS BRANCH,PHARMACEUT EVALUAT SECT CANBERRA ACT AUSTRALIA
Titolo Testata:
British journal of clinical pharmacology
fascicolo: 4, volume: 40, anno: 1995,
pagine: 407 - 410
SICI:
0306-5251(1995)40:4<407:MTMUON>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Keywords:
DRUG UTILIZATION; MARKET UPTAKE; PHARMACOEPIDEMIOLOGY; DRUG SUBSIDY;
Tipo documento:
Note
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
5
Recensione:
Indirizzi per estratti:
Citazione:
D.J. Birkett e P. Mcmanus, "MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDYIN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THETRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE", British journal of clinical pharmacology, 40(4), 1995, pp. 407-410

Abstract

The market uptake of five drugs following subsidy listing in Australia during the period 1990 to 1992 has been modelled using the sigmoid E(max) model for drug-receptor binding. Utilisation trends for simvastatin, omeprazole, budesonide, fluoxetine and moclobemide in defined daily dose (DDD) per 1000 population per day were smoothed by expressing as rolling annual averages. The results indicate good fits of the model to the data except for omeprazole, with good estimates of uptake rate and eventual maximum utilisation. Substantial differences between the drugs occurred in uptake rate which may be related to public education campaigns on asthma and coronary heart disease occurring during therelease period. The very slow uptake of omeprazole relative to other drugs is likely to be due to restrictions on subsidised use. Modellingthe market uptake rate and eventual utilisation of new drugs is useful as an aid to regulatory, quality use of medicines and financial decisions and allows comparisons between drugs to investigate factors important in market uptake.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 21:54:34